Plasma AR and abiraterone-resistant prostate cancer

Alessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca, Anuradha Jayaram, Nicola Casiraghi, Daniel Wetterskog, Samanta Salvi, Dino Amadori, Zafeiris Zafeiriou, Pasquale Rescigno, Diletta Bianchini, Giorgia Gurioli, Valentina Casadio, Suzanne Carreira, Jane Goodall, Anna Wingate, Roberta Ferraldeschi, Nina Tunariu, Penny Flohr, Ugo De GiorgiJohann S. De Bono, Francesca Demichelis, Gerhardt Attard

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

Androgen receptor (AR) gene aberrations are rare in prostate cancer before primary hormone treatment but emerge with castration resistance. To determine AR gene status using a minimally invasive assay that could have broad clinical utility, we developed a targeted next-generation sequencing approach amenable to plasma DNA, covering all AR coding bases and genomic regions that are highly informative in prostate cancer. We sequenced 274 plasma samples from 97 castration-resistant prostate cancer patients treated with abiraterone at two institutions. We controlled for normal DNA in patients' circulation and detected a sufficiently high tumor DNA fraction to quantify AR copy number state in 217 samples (80 patients). Detection of AR copy number gain and point mutations in plasma were inversely correlated, supported further by the enrichment of nonsynonymous versus synonymous mutations in AR copy number normal as opposed to AR gain samples. Whereas AR copy number was unchanged from before treatment to progression and no mutant AR alleles showed signal for acquired gain, we observed emergence of T878A or L702H AR amino acid changes in 13% of tumors at progression on abiraterone. Patients with AR gain or T878A or L702H before abiraterone (45%) were 4.9 and 7.8 times less likely to have a ≥50 or ≥90% decline in prostate-specific antigen (PSA), respectively, and had a significantly worse overall [hazard ratio (HR), 7.33; 95% confidence interval (CI), 3.51 to 15.34; P = 1.3 × 10-9) and progression-free (HR, 3.73; 95% CI, 2.17 to 6.41; P = 5.6 × 10-7) survival. Evaluation of plasma AR by next-generation sequencing could identify cancers with primary resistance to abiraterone.

Original languageEnglish
Article number312re10
JournalScience Translational Medicine
Volume7
Issue number312
DOIs
Publication statusPublished - Nov 4 2015

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Castration
abiraterone
DNA
Confidence Intervals
Neoplasms
Prostate-Specific Antigen
Point Mutation
Genes
Alleles
Hormones

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Romanel, A., Tandefelt, D. G., Conteduca, V., Jayaram, A., Casiraghi, N., Wetterskog, D., ... Attard, G. (2015). Plasma AR and abiraterone-resistant prostate cancer. Science Translational Medicine, 7(312), [312re10]. https://doi.org/10.1126/scitranslmed.aac9511

Plasma AR and abiraterone-resistant prostate cancer. / Romanel, Alessandro; Tandefelt, Delila Gasi; Conteduca, Vincenza; Jayaram, Anuradha; Casiraghi, Nicola; Wetterskog, Daniel; Salvi, Samanta; Amadori, Dino; Zafeiriou, Zafeiris; Rescigno, Pasquale; Bianchini, Diletta; Gurioli, Giorgia; Casadio, Valentina; Carreira, Suzanne; Goodall, Jane; Wingate, Anna; Ferraldeschi, Roberta; Tunariu, Nina; Flohr, Penny; De Giorgi, Ugo; De Bono, Johann S.; Demichelis, Francesca; Attard, Gerhardt.

In: Science Translational Medicine, Vol. 7, No. 312, 312re10, 04.11.2015.

Research output: Contribution to journalArticle

Romanel, A, Tandefelt, DG, Conteduca, V, Jayaram, A, Casiraghi, N, Wetterskog, D, Salvi, S, Amadori, D, Zafeiriou, Z, Rescigno, P, Bianchini, D, Gurioli, G, Casadio, V, Carreira, S, Goodall, J, Wingate, A, Ferraldeschi, R, Tunariu, N, Flohr, P, De Giorgi, U, De Bono, JS, Demichelis, F & Attard, G 2015, 'Plasma AR and abiraterone-resistant prostate cancer', Science Translational Medicine, vol. 7, no. 312, 312re10. https://doi.org/10.1126/scitranslmed.aac9511
Romanel A, Tandefelt DG, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D et al. Plasma AR and abiraterone-resistant prostate cancer. Science Translational Medicine. 2015 Nov 4;7(312). 312re10. https://doi.org/10.1126/scitranslmed.aac9511
Romanel, Alessandro ; Tandefelt, Delila Gasi ; Conteduca, Vincenza ; Jayaram, Anuradha ; Casiraghi, Nicola ; Wetterskog, Daniel ; Salvi, Samanta ; Amadori, Dino ; Zafeiriou, Zafeiris ; Rescigno, Pasquale ; Bianchini, Diletta ; Gurioli, Giorgia ; Casadio, Valentina ; Carreira, Suzanne ; Goodall, Jane ; Wingate, Anna ; Ferraldeschi, Roberta ; Tunariu, Nina ; Flohr, Penny ; De Giorgi, Ugo ; De Bono, Johann S. ; Demichelis, Francesca ; Attard, Gerhardt. / Plasma AR and abiraterone-resistant prostate cancer. In: Science Translational Medicine. 2015 ; Vol. 7, No. 312.
@article{e056a0e503774bcc982f825b70b18841,
title = "Plasma AR and abiraterone-resistant prostate cancer",
abstract = "Androgen receptor (AR) gene aberrations are rare in prostate cancer before primary hormone treatment but emerge with castration resistance. To determine AR gene status using a minimally invasive assay that could have broad clinical utility, we developed a targeted next-generation sequencing approach amenable to plasma DNA, covering all AR coding bases and genomic regions that are highly informative in prostate cancer. We sequenced 274 plasma samples from 97 castration-resistant prostate cancer patients treated with abiraterone at two institutions. We controlled for normal DNA in patients' circulation and detected a sufficiently high tumor DNA fraction to quantify AR copy number state in 217 samples (80 patients). Detection of AR copy number gain and point mutations in plasma were inversely correlated, supported further by the enrichment of nonsynonymous versus synonymous mutations in AR copy number normal as opposed to AR gain samples. Whereas AR copy number was unchanged from before treatment to progression and no mutant AR alleles showed signal for acquired gain, we observed emergence of T878A or L702H AR amino acid changes in 13{\%} of tumors at progression on abiraterone. Patients with AR gain or T878A or L702H before abiraterone (45{\%}) were 4.9 and 7.8 times less likely to have a ≥50 or ≥90{\%} decline in prostate-specific antigen (PSA), respectively, and had a significantly worse overall [hazard ratio (HR), 7.33; 95{\%} confidence interval (CI), 3.51 to 15.34; P = 1.3 × 10-9) and progression-free (HR, 3.73; 95{\%} CI, 2.17 to 6.41; P = 5.6 × 10-7) survival. Evaluation of plasma AR by next-generation sequencing could identify cancers with primary resistance to abiraterone.",
author = "Alessandro Romanel and Tandefelt, {Delila Gasi} and Vincenza Conteduca and Anuradha Jayaram and Nicola Casiraghi and Daniel Wetterskog and Samanta Salvi and Dino Amadori and Zafeiris Zafeiriou and Pasquale Rescigno and Diletta Bianchini and Giorgia Gurioli and Valentina Casadio and Suzanne Carreira and Jane Goodall and Anna Wingate and Roberta Ferraldeschi and Nina Tunariu and Penny Flohr and {De Giorgi}, Ugo and {De Bono}, {Johann S.} and Francesca Demichelis and Gerhardt Attard",
year = "2015",
month = "11",
day = "4",
doi = "10.1126/scitranslmed.aac9511",
language = "English",
volume = "7",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "312",

}

TY - JOUR

T1 - Plasma AR and abiraterone-resistant prostate cancer

AU - Romanel, Alessandro

AU - Tandefelt, Delila Gasi

AU - Conteduca, Vincenza

AU - Jayaram, Anuradha

AU - Casiraghi, Nicola

AU - Wetterskog, Daniel

AU - Salvi, Samanta

AU - Amadori, Dino

AU - Zafeiriou, Zafeiris

AU - Rescigno, Pasquale

AU - Bianchini, Diletta

AU - Gurioli, Giorgia

AU - Casadio, Valentina

AU - Carreira, Suzanne

AU - Goodall, Jane

AU - Wingate, Anna

AU - Ferraldeschi, Roberta

AU - Tunariu, Nina

AU - Flohr, Penny

AU - De Giorgi, Ugo

AU - De Bono, Johann S.

AU - Demichelis, Francesca

AU - Attard, Gerhardt

PY - 2015/11/4

Y1 - 2015/11/4

N2 - Androgen receptor (AR) gene aberrations are rare in prostate cancer before primary hormone treatment but emerge with castration resistance. To determine AR gene status using a minimally invasive assay that could have broad clinical utility, we developed a targeted next-generation sequencing approach amenable to plasma DNA, covering all AR coding bases and genomic regions that are highly informative in prostate cancer. We sequenced 274 plasma samples from 97 castration-resistant prostate cancer patients treated with abiraterone at two institutions. We controlled for normal DNA in patients' circulation and detected a sufficiently high tumor DNA fraction to quantify AR copy number state in 217 samples (80 patients). Detection of AR copy number gain and point mutations in plasma were inversely correlated, supported further by the enrichment of nonsynonymous versus synonymous mutations in AR copy number normal as opposed to AR gain samples. Whereas AR copy number was unchanged from before treatment to progression and no mutant AR alleles showed signal for acquired gain, we observed emergence of T878A or L702H AR amino acid changes in 13% of tumors at progression on abiraterone. Patients with AR gain or T878A or L702H before abiraterone (45%) were 4.9 and 7.8 times less likely to have a ≥50 or ≥90% decline in prostate-specific antigen (PSA), respectively, and had a significantly worse overall [hazard ratio (HR), 7.33; 95% confidence interval (CI), 3.51 to 15.34; P = 1.3 × 10-9) and progression-free (HR, 3.73; 95% CI, 2.17 to 6.41; P = 5.6 × 10-7) survival. Evaluation of plasma AR by next-generation sequencing could identify cancers with primary resistance to abiraterone.

AB - Androgen receptor (AR) gene aberrations are rare in prostate cancer before primary hormone treatment but emerge with castration resistance. To determine AR gene status using a minimally invasive assay that could have broad clinical utility, we developed a targeted next-generation sequencing approach amenable to plasma DNA, covering all AR coding bases and genomic regions that are highly informative in prostate cancer. We sequenced 274 plasma samples from 97 castration-resistant prostate cancer patients treated with abiraterone at two institutions. We controlled for normal DNA in patients' circulation and detected a sufficiently high tumor DNA fraction to quantify AR copy number state in 217 samples (80 patients). Detection of AR copy number gain and point mutations in plasma were inversely correlated, supported further by the enrichment of nonsynonymous versus synonymous mutations in AR copy number normal as opposed to AR gain samples. Whereas AR copy number was unchanged from before treatment to progression and no mutant AR alleles showed signal for acquired gain, we observed emergence of T878A or L702H AR amino acid changes in 13% of tumors at progression on abiraterone. Patients with AR gain or T878A or L702H before abiraterone (45%) were 4.9 and 7.8 times less likely to have a ≥50 or ≥90% decline in prostate-specific antigen (PSA), respectively, and had a significantly worse overall [hazard ratio (HR), 7.33; 95% confidence interval (CI), 3.51 to 15.34; P = 1.3 × 10-9) and progression-free (HR, 3.73; 95% CI, 2.17 to 6.41; P = 5.6 × 10-7) survival. Evaluation of plasma AR by next-generation sequencing could identify cancers with primary resistance to abiraterone.

UR - http://www.scopus.com/inward/record.url?scp=84947245381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947245381&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aac9511

DO - 10.1126/scitranslmed.aac9511

M3 - Article

AN - SCOPUS:84947245381

VL - 7

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 312

M1 - 312re10

ER -